Pertuzumab, marketed under the brand name Perjeta, is a monoclonal antibody used in the treatment of certain types of cancer. It is specifically designed to target the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some types of breast cancer and other solid tumors.
